NO20073900L - Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer - Google Patents

Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer

Info

Publication number
NO20073900L
NO20073900L NO20073900A NO20073900A NO20073900L NO 20073900 L NO20073900 L NO 20073900L NO 20073900 A NO20073900 A NO 20073900A NO 20073900 A NO20073900 A NO 20073900A NO 20073900 L NO20073900 L NO 20073900L
Authority
NO
Norway
Prior art keywords
lgg
medicament
prevention
manufacture
treatment
Prior art date
Application number
NO20073900A
Other languages
English (en)
Norwegian (no)
Inventor
Udo Herz
Harald Renz
Nicole Bluemer
Holger Garn
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36698734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073900(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/106,792 external-priority patent/US20060233772A1/en
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of NO20073900L publication Critical patent/NO20073900L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20073900A 2005-04-15 2007-07-25 Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer NO20073900L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/106,792 US20060233772A1 (en) 2005-04-15 2005-04-15 Method for preventing or treating the development of respiratory allergies
US11/144,287 US7303745B2 (en) 2005-04-15 2005-06-03 Method for preventing or treating the development of respiratory allergies
PCT/US2006/010418 WO2006113035A1 (en) 2005-04-15 2006-03-22 Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies

Publications (1)

Publication Number Publication Date
NO20073900L true NO20073900L (no) 2008-01-10

Family

ID=36698734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073900A NO20073900L (no) 2005-04-15 2007-07-25 Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer

Country Status (14)

Country Link
US (6) US7303745B2 (pt)
EP (1) EP1868623B1 (pt)
KR (2) KR20130058767A (pt)
CN (1) CN105832774B (pt)
BR (1) BRPI0609077A2 (pt)
CA (3) CA2881536C (pt)
ES (1) ES2599156T3 (pt)
MX (1) MX2007012538A (pt)
MY (2) MY147175A (pt)
NO (1) NO20073900L (pt)
PL (1) PL1868623T3 (pt)
RU (1) RU2435598C2 (pt)
TW (1) TWI369210B (pt)
WO (1) WO2006113035A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
BRPI0708701A2 (pt) * 2006-03-10 2011-06-07 Nutricia Nv uso de um sacarìdeo não digerìvel solúvel em água
WO2008064489A1 (en) * 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
EP1974734A1 (en) † 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
MY159076A (en) * 2007-11-08 2016-12-15 Nestec Sa Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
US9483911B2 (en) 2008-04-30 2016-11-01 Bally Gaming, Inc. Information distribution in gaming networks
PT2285387E (pt) * 2008-06-13 2016-02-09 Nutricia Nv Nutrição para a prevenção de infeções
WO2009151315A1 (en) * 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010071421A1 (en) * 2008-12-17 2010-06-24 N.V. Nutricia Probiotics for the treatment and/or prevention of pulmonary hypertension
EP2295535A1 (en) * 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
JP4942831B2 (ja) * 2010-03-19 2012-05-30 株式会社キティー 抗アレルギー用組成物
WO2013187755A1 (en) 2012-06-14 2013-12-19 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
WO2019169258A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5840318A (en) 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
ATE265207T1 (de) 1997-02-21 2004-05-15 Abbott Lab Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2351469A1 (en) 1998-12-15 2000-06-22 Susan Marie Kaup Method and composition for the maintenance and restitution of gut integrity
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
CA2374937A1 (en) 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
FI113741B (fi) 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
WO2001058465A2 (en) 2000-02-10 2001-08-16 Gregor Reid Probiotic therapy for newborns
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US20030180260A1 (en) * 2000-06-19 2003-09-25 Clancy Robert Llewellyn Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
CA2436264C (en) * 2001-02-06 2014-01-28 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
CA2432929A1 (en) * 2001-02-16 2002-08-29 Joseph Matthew Colacino Antiviral method of use
EP1239032A1 (en) 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1243273A1 (en) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1260227A1 (en) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
ES2192151B1 (es) * 2002-03-15 2005-02-01 Universidad Politecnica De Valencia Linea de retardo multiple basada en awg y diferentes tramos de un medio optico dispersivo.
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
EP1596872B1 (en) 2003-01-24 2011-06-22 Flora Technology Inc. Compositions and methods for restoring bacterial flora
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies

Also Published As

Publication number Publication date
WO2006113035A1 (en) 2006-10-26
US20080085267A1 (en) 2008-04-10
RU2007137994A (ru) 2009-05-20
RU2435598C2 (ru) 2011-12-10
US7837989B2 (en) 2010-11-23
US20060233773A1 (en) 2006-10-19
US20080118484A1 (en) 2008-05-22
BRPI0609077A2 (pt) 2010-02-17
EP1868623B1 (en) 2016-08-31
MY162223A (en) 2017-05-31
CA2991508A1 (en) 2006-10-26
US20080118485A1 (en) 2008-05-22
US7867485B2 (en) 2011-01-11
TWI369210B (en) 2012-08-01
US20080131413A1 (en) 2008-06-05
CA2991508C (en) 2019-06-25
US7923006B2 (en) 2011-04-12
TW200716145A (en) 2007-05-01
CN105832774B (zh) 2020-03-06
MX2007012538A (es) 2007-12-10
US20080118483A1 (en) 2008-05-22
CA2604846A1 (en) 2006-10-26
KR20070122479A (ko) 2007-12-31
CA2604846C (en) 2015-05-05
KR20130058767A (ko) 2013-06-04
MY147175A (en) 2012-11-14
KR101277447B1 (ko) 2013-06-28
EP1868623A1 (en) 2007-12-26
PL1868623T3 (pl) 2017-03-31
US7303745B2 (en) 2007-12-04
CA2881536C (en) 2018-02-13
CA2881536A1 (en) 2006-10-26
ES2599156T3 (es) 2017-01-31
US7867486B2 (en) 2011-01-11
CN105832774A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
NO20073900L (no) Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
CY1116828T1 (el) Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα
CR20140465A (es) Proteinas de union a interleuquina-13
TW200744642A (en) Novel peptides for use in the treatment of obesity
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE543907T1 (de) Stresstolerante baumwollpflanzen
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
NO20076206L (no) Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ
HN2012000012A (es) Inhibidores de bace
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
DK1962869T3 (da) Behandling af luftvejssygdomme
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE517877T1 (de) Neue arzneimittel zur behandlung von atemwegserkrankungen
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ATE433459T1 (de) Desoxo-nonadepsipeptide

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MJN U.S. HOLDINGS LLC, US

FC2A Withdrawal, rejection or dismissal of laid open patent application